JumpStart announces two JumpStart Ventures investments

NewsGuard 100/100 Score
JumpStart Inc., the Northeast Ohio venture development organization that accelerates the progress of high growth early-stage businesses, announces two JumpStart Ventures investments. Absorbent Materials Company LLC (dba ABSMaterials LLC), a company developing a novel, silica-based material that absorbs toxins in water, and MAX Endoscopy Inc., a medical device manufacturer using fiber optics to guide the treatment of hemorrhoids, each received investment commitments of $250,000.

ABSMaterials' patented "swelling glass," developed by Dr. Paul Edmiston from the College of Wooster, is similar to a highly tensioned, nano-matrix of glass. When it comes in contact with a volatile organic compound in water, such as fuel oils, chlorinated solvents, and hexamine, the glass absorbs the volatile molecules within the compound without reacting with the water. ABSMaterials is currently marketing three variations of the material to firms and government agencies contracted to clean up or remediate toxic groundwater contamination sites.

"We are excited to work with JumpStart Ventures as we continue to prove consistent remediation success with our material," said ABSMaterials Chief Executive Officer, Stephen Spoonamore.

MAX Endoscopy's patent-pending device, called the PRECISION Endoscopic Infrared Coagulator(TM), utilizes infrared light (which coagulates blood vessels) using flexible fiber optic technology. When used in a scope, the result is increased accuracy and visual confirmation of successful treatment. MAX Endoscopy has received FDA clearance on the system and is currently selling to gastroenterologists and colorectal surgeons.

"With this investment, we are beginning to lay the foundation for scalable penetration into the large, profitable, and growing gastrointestinal endoscopy market," said Robert Stuba, President and CEO of MAX Endoscopy.

With these two investments, JumpStart Ventures has invested in four new companies in 2009's fourth quarter, bringing its portfolio of high growth, early-stage companies to 44.

SOURCE JumpStart, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New compound shows promise as a more effective treatment for schistosomiasis